TAKEDA PHARMACEUTICAL CO LTD - SPONSORED ADS (TAK) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class
Equity / SPONSORED ADS
Symbol
TAK on NYSE
Price per share
$15.59
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
85,200,989
Total reported value
$1,247,351,823
% of total 13F portfolios
0%
Share change
+7,438,953
Value change
+$106,200,543
Number of holders
321
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

As of 30 Sep 2025, 321 institutional investors reported holding 85,200,989 shares of TAKEDA PHARMACEUTICAL CO LTD - SPONSORED ADS (TAK).

Institutional Holders of TAKEDA PHARMACEUTICAL CO LTD - SPONSORED ADS (TAK) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 491,802 $7,679,182 -$291,946 $15.59 25
2025 Q3 85,200,989 $1,247,351,823 +$106,200,543 $14.64 321
2025 Q2 77,806,551 $1,202,786,823 +$106,862,939 $15.46 308
2025 Q1 71,086,297 $1,057,032,461 -$156,051 $14.87 299
2024 Q4 72,012,903 $953,504,824 -$55,385,495 $13.24 291
2024 Q3 71,553,169 $1,015,380,211 +$20,522,204 $14.22 296
2024 Q2 72,061,993 $940,730,763 -$86,515,524 $12.94 282
2024 Q1 78,179,295 $1,087,229,372 -$75,255,783 $13.89 310
2023 Q4 83,203,742 $1,187,331,253 +$44,580,205 $14.27 298
2023 Q3 80,186,873 $1,238,629,561 -$62,722,531 $15.47 305
2023 Q2 83,777,518 $1,316,226,289 -$49,940,581 $15.71 302
2023 Q1 81,595,481 $1,344,608,359 +$254,847,296 $16.48 288
2022 Q4 67,666,668 $1,057,415,212 +$60,430,987 $15.60 270
2022 Q3 63,286,946 $821,024,064 +$94,369,882 $12.97 250
2022 Q2 56,642,643 $795,035,114 +$69,132,475 $14.04 251
2022 Q1 55,744,115 $796,890,075 -$259,336,061 $14.32 257
2021 Q4 71,118,095 $970,947,825 -$282,516,518 $13.63 262
2021 Q3 91,724,629 $1,500,956,919 -$41,562,730 $16.38 269
2021 Q2 94,721,080 $1,594,590,144 -$223,728,219 $16.83 281
2021 Q1 107,236,456 $1,956,547,194 -$5,542,824 $18.26 294
2020 Q4 108,387,616 $1,971,794,573 +$47,702,291 $18.20 283
2020 Q3 107,376,034 $1,906,201,737 -$77,868,691 $17.84 290
2020 Q2 110,211,131 $1,975,638,827 -$82,796,616 $17.93 284
2020 Q1 115,444,746 $1,753,768,853 -$255,755,250 $15.18 279
2019 Q4 129,205,921 $2,550,743,065 -$263,240,299 $19.73 315
2019 Q3 141,442,566 $2,431,872,070 -$10,065,934 $17.20 287
2019 Q2 144,946,940 $2,566,665,939 -$492,403,542 $17.70 318
2019 Q1 177,136,508 $3,606,435,287 +$2,478,311,203 $20.37 357
2018 Q4 53,758,263 $907,732,778 +$834,155,233 $16.82 79
2018 Q3 2,915,346 $62,314,000 +$9,170,362 $21.37 14
2018 Q2 2,486,238 $52,071,000 +$10,805,823 $20.90 12
2018 Q1 1,884,207 $45,983,000 +$5,617,797 $24.55 8
2017 Q4 1,652,653 $47,012,000 +$7,825,828 $28.30 7
2017 Q3 1,377,452 $38,131,326 +$9,513,045 $27.54 6
2017 Q2 1,032,922 $26,255,135 +$3,289,775 $25.42 5
2017 Q1 903,509 $21,336,985 +$7,304,729 $23.63 5
2016 Q4 598,154 $12,427,746 +$279,511 $20.78 6
2016 Q3 583,858 $13,971,000 +$3,234,562 $23.88 4
2016 Q2 449,504 $9,682,809 -$5,836,092 $21.54 6
2016 Q1 720,508 $16,443,917 +$3,726,373 $22.82 7
2015 Q4 557,111 $13,958,103 +$8,511,509 $25.02 8
2015 Q3 231,689 $5,064,000 -$7,911,833 $21.88 8
2015 Q2 556,323 $13,465,000 +$636,076 $24.16 7
2015 Q1 529,554 $13,251,000 +$1,844,506 $25.00 8
2014 Q4 455,916 $9,476,000 -$83,573 $20.84 8
2014 Q3 459,996 $10,000,000 +$530,655 $21.75 8
2014 Q2 435,563 $10,116,000 -$6,899,908 $23.19 7
2014 Q1 726,088 $17,232,000 +$5,027,584 $23.75 9